Trial reportEuropean heart journal2015
Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study.
Trial report in European heart journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 76 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of the PCSK9 Antibody AliroCuMab on Coronary Atherosclerosis in PatieNts With Acute Myocardial Infarction: A Serial, Multivessel, Intravascular Ultrasound, Near-Infrared Spectroscopy And Optical Coherence Tomography Imaging Study
The Effects of Tirzepatide on Coronary Plaque Lipid Content and Myocardial Microvascular Function in Overweight and Obese People With Coronary Disease - The IDEAL-COR Study
Who cites it
76 citing papers in PubMed, 2 syntheses or guidelines pooled it, 210 citations in OpenAlex.
- The effects of lipid-lowering therapy on coronary plaque regression: a systematic review and meta-analysis.Scientific reports · 2021Pooled it
- The Effect of Statin Therapy on Coronary Plaque Composition Using Virtual Histology Intravascular Ultrasound: A Meta-Analysis.PloS one · 2015Pooled it
- Changes in non-culprit coronary lesions with PCSK9 inhibitors: the randomised, placebo-controlled FITTER trial.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025Trial
- Discordance in the diagnostic assessment of vulnerable plaques between radiofrequency intravascular ultrasound versus optical coherence tomography among patients with acute myocardial infarction: insights from the IBIS-4 study.The international journal of cardiovascular imaging · 2021Trial
- Short-term lesion-level impact of extensive LDL-C reduction with statins and PCSK9 inhibitors: a pre-specified subgroup analysis of the randomized FITTER trial.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- A novel framework for fully automated co-registration of intravascular ultrasound and optical coherence tomography imaging data.European heart journal. Digital health · 2026Article
- Intracoronary Imaging for the Management of Vulnerable Plaques.Journal of clinical medicine · 2026Review
- Percutaneous coronary intervention as an independent predictor of non-target lesion progression in 1658 patients with coronary artery disease.Theranostics · 2026Article
- Coronary Plaque Regression: A Review of the Role of Lipid-Lowering Agents.The International journal of angiology : official publication of the International College of Angiology, Inc · 2025Review
- Targeting Vulnerable Plaques in Coronary Artery Disease: Detecting Risk, Preventing Events.Current cardiology reports · 2025Review
- Prognostic Role and Therapeutic Implications of Intravascular Optical Coherence Tomography Detected Coronary Plaque Microstructures in Patients with Coronary Artery Disease.Journal of clinical medicine · 2025Review
- Artificial Intelligence-Led Whole Coronary Artery OCT Analysis; Validation and Identification of Drug Efficacy and Higher-Risk Plaques.Circulation. Cardiovascular imaging · 2025Article
- Advances in coronary imaging of atherosclerotic plaques.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025Review
- The sequence of changes in intravascular imaging findings during lipid-lowering therapy and its implication.Nature cardiovascular research · 2025Review
- Perspectives in the Diagnosis, Clinical Impact, and Management of the Vulnerable Plaque.Journal of clinical medicine · 2025Review
- Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy.Current atherosclerosis reports · 2025Review
- Expert Consensus on the Diagnosis and Management of Carotid Atherosclerotic Plaque: Pathophysiology, Clinical Management, and Preventive Approaches.International journal of medical sciences · 2025Review
- Statin therapy in primary and secondary cardiovascular disease prevention.Current atherosclerosis reports · 2024Review
- [Beyond the plaque: immunological implications of risk factors in atherosclerosis].Archivos de cardiologia de Mexico · 2024Review
- Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
16 authors at 8 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe effect of long-term high-intensity statin therapy on coronary atherosclerosis among patients with acute ST-segment elevation myocardial infarction (STEMI) is unknown. The aim of this study was to quantify the impact of high-intensity statin therapy on plaque burden, composition, and phenotype in non-infarct-related arteries of STEMI patients undergoing primary percutaneous coronary intervention (PCI). METHODS AND
resultsBetween September 2009 and January 2011, 103 STEMI patients underwent intravascular ultrasonography (IVUS) and radiofrequency ultrasonography (RF-IVUS) of the two non-infarct-related epicardial coronary arteries (non-IRA) after successful primary PCI. Patients were treated with high-intensity rosuvastatin (40 mg/day) throughout 13 months and serial intracoronary imaging with the analysis of matched segments was available for 82 patients with 146 non-IRA. The primary IVUS end-point was the change in per cent atheroma volume (PAV). After 13 months, low-density lipoprotein cholesterol (LDL-C) had decreased from a median of 3.29 to 1.89 mmol/L (P < 0.001), and high-density lipoprotein cholesterol (HDL-C) levels had increased from 1.10 to 1.20 mmol/L (P < 0.001). PAV of the non-IRA decreased by -0.9% (95% CI: -1.56 to -0.25, P = 0.007). Patients with regression in at least one non-IRA were more common (74%) than those without (26%). Per cent necrotic core remained unchanged (-0.05%, 95% CI: -1.05 to 0.96%, P = 0.93) as did the number of RF-IVUS defined thin cap fibroatheromas (124 vs. 116, P = 0.15).
conclusionHigh-intensity rosuvastatin therapy over 13 months is associated with regression of coronary atherosclerosis in non-infarct-related arteries without changes in RF-IVUS defined necrotic core or plaque phenotype among STEMI patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.